CYCLOPHOSPHAMIDE, EPIRUBICIN, AND FLUOROURACIL VERSUS DOSE-DENSE EPIRUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL VERSUS DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL IN NODE-POSITIVE OR HIGH-RISK NODE-NEGATIVE BREAST CANCER

BURNELL, M., LEVINE, M.N., CHAPMAN, J.A., BRAMWELL, V., GELMON, K., & WALLEY, B.. (2010). CYCLOPHOSPHAMIDE, EPIRUBICIN, AND FLUOROURACIL VERSUS DOSE-DENSE EPIRUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL VERSUS DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL IN NODE-POSITIVE OR HIGH-RISK NODE-NEGATIVE BREAST CANCER. JOURNAL OF CLINICAL ONCOLOGY, 28(1), 77-82. SID. https://sid.ir/paper/578619/en

BURNELL M., LEVINE M.N., CHAPMAN J.A., BRAMWELL V., GELMON K., WALLEY B.. CYCLOPHOSPHAMIDE, EPIRUBICIN, AND FLUOROURACIL VERSUS DOSE-DENSE EPIRUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL VERSUS DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL IN NODE-POSITIVE OR HIGH-RISK NODE-NEGATIVE BREAST CANCER. JOURNAL OF CLINICAL ONCOLOGY[Internet]. 2010;28(1):77-82. Available from: https://sid.ir/paper/578619/en

M. BURNELL, M.N. LEVINE, J.A. CHAPMAN, V. BRAMWELL, K. GELMON, and B. WALLEY, “CYCLOPHOSPHAMIDE, EPIRUBICIN, AND FLUOROURACIL VERSUS DOSE-DENSE EPIRUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL VERSUS DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL IN NODE-POSITIVE OR HIGH-RISK NODE-NEGATIVE BREAST CANCER,” JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 1, pp. 77–82, 2010, [Online]. Available: https://sid.ir/paper/578619/en